EP1233776A4 - Urotensin-ii cyclic analogs - Google Patents

Urotensin-ii cyclic analogs

Info

Publication number
EP1233776A4
EP1233776A4 EP00980841A EP00980841A EP1233776A4 EP 1233776 A4 EP1233776 A4 EP 1233776A4 EP 00980841 A EP00980841 A EP 00980841A EP 00980841 A EP00980841 A EP 00980841A EP 1233776 A4 EP1233776 A4 EP 1233776A4
Authority
EP
European Patent Office
Prior art keywords
urotensin
cyclic analogs
analogs
cyclic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00980841A
Other languages
German (de)
French (fr)
Other versions
EP1233776A1 (en
Inventor
Dashyant Dhanak
Steven D Knight
Gregory L Warren
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1233776A1 publication Critical patent/EP1233776A1/en
Publication of EP1233776A4 publication Critical patent/EP1233776A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57509—Corticotropin releasing factor [CRF] (Urotensin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
EP00980841A 1999-11-29 2000-11-29 Urotensin-ii cyclic analogs Withdrawn EP1233776A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16796099P 1999-11-29 1999-11-29
US167960P 1999-11-29
PCT/US2000/032407 WO2001037856A1 (en) 1999-11-29 2000-11-29 Urotensin-ii cyclic analogs

Publications (2)

Publication Number Publication Date
EP1233776A1 EP1233776A1 (en) 2002-08-28
EP1233776A4 true EP1233776A4 (en) 2003-05-07

Family

ID=22609533

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00980841A Withdrawn EP1233776A4 (en) 1999-11-29 2000-11-29 Urotensin-ii cyclic analogs

Country Status (3)

Country Link
EP (1) EP1233776A4 (en)
JP (1) JP2003514867A (en)
WO (1) WO2001037856A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITFI20030238A1 (en) 2003-09-11 2005-03-12 Paolo Grieco UROTENSIN ANTAGONIST CYCLIC PEPTIDES-II
US20090060861A1 (en) * 2005-05-25 2009-03-05 Novo Nordisk A/S Stabilized Polypeptide Formulations
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
ITFI20070032A1 (en) * 2007-02-09 2008-08-10 Alfredo Budillon LIGANDS OF PEPTIDIC AND NON-PEPTIDIC NATURE OF THE UT RECEIVER OF UROTENSIN-II, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR USE.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY147327A (en) * 1995-06-29 2012-11-30 Novartis Ag Somatostatin peptides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
GRIECO PAOLO ET AL: "Design, synthesis, conformational analysis, and biological studies of urotensin-II lactam analogues.", BIOORGANIC & MEDICINAL CHEMISTRY, vol. 10, no. 12, 20 December 2002 (2002-12-20), pages 3731 - 3739, XP002234088, ISSN: 0968-0896 *
PERKINS T D J ET AL: "Molecular modelling and design of analogues of the peptide hormone Urotensin II", BIOCHEMICAL SOCIETY TRANSACTIONS, COLCHESTER, ESSEX, GB, vol. 18, no. PART 5, October 1990 (1990-10-01), pages 918 - 919, XP002110993, ISSN: 0300-5127 *
See also references of WO0137856A1 *
THURIEAU C ET AL: "A new somatostatin analog with optimized ring size inhibits neointima formation induced by balloon injury in rats without altering growth hormone release", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 30, no. 2, 1995, pages 115 - 122, XP004040126, ISSN: 0223-5234 *
ZHANG WEI-JUN ET AL: "Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: Conformational and biological implications.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 14, 1996, pages 2738 - 2744, XP002234087, ISSN: 0022-2623 *

Also Published As

Publication number Publication date
EP1233776A1 (en) 2002-08-28
WO2001037856A1 (en) 2001-05-31
JP2003514867A (en) 2003-04-22

Similar Documents

Publication Publication Date Title
AU4114201A (en) Cyclic compounds
HUP0202812A3 (en) Novel bicyclonucleoside analogues
EP1353683A4 (en) Ghrelin analogs
EG23909A (en) Vatamin d, analogs
AU142191S (en) Cap
ZA200108018B (en) Pyrrolidincarbonylamino cyclic disulfides.
PL345037A1 (en) Cyclic somatostatin analogs
HK1045312A1 (en) Cyclic compound
GB2354448B (en) Improved laryngoscope
PL357875A1 (en) Cyclic hexapeptide derivatives
EP1233774A4 (en) Urotensin-ii analogs
PL351523A1 (en) Novel 8a- and 9a-15-membered lactams
IL129179A0 (en) Cyclic glycerophosphates and analogs thereof
EP1233776A4 (en) Urotensin-ii cyclic analogs
AU139720S (en) Cap
EP1312612A4 (en) Cyclic peptide derivative
GB9929433D0 (en) Cyclic compound
GB9905498D0 (en) Expression
GB2396137B (en) Improved drawing instruments
ZA200205115B (en) Novel cyclic compounds.
TW463788U (en) Improved structure for cap
AU3409501A (en) Cyclic hexapeptide derivatives
GB2356377B (en) Improved drawing instruments
AU141826S (en) Cap
GB9920251D0 (en) Cap

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020604

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

A4 Supplementary search report drawn up and despatched

Effective date: 20030321

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20060601